Living with Diabetes

Blog

  • GERD – latest

    I see the surgeon next week.

    I ran the following past my principal and he was cool with it — I’m seeing a surgeon next week and I am planning to get an operation over the break, is it okay with you, if I do it exam week — that will give me an extra week to recover. He said he was sure he could get anyone to give a test. I do need to spend some time and come up with a decent exam for the ELI kiddos,

    I’ve also run this past the husband.

    Here’s the deal. Every time I work out, I have problems with heartburn. Almost every single night it wakes me up. It’s not as bad as it was with the expired Nexxium — that was the utter worse I’ve seen in ages. But I am still waking up. Most of the time I can roll over and go back to sleep but a lot of times I go ahead and get up, or have to get up and deal with it.

    I was having chest pains after lunch today. I’m 99% sure it was GERD. This is really sucking.

    Basically, the last time I was able to get rid of the GERD sympthoms, I was on Propulsid (sp), and had lost about 50 more pounds than I’ve lost so far. Well, the Propulsid isn’t available, and it’s going to be another year before I see 50 more pounds.

    Sigh.

    Well, at least I have my ducks in a row.

  • GERD – latest

    I see the surgeon next week.

    I ran the following past my principal and he was cool with it — I’m seeing a surgeon next week and I am planning to get an operation over the break, is it okay with you, if I do it exam week — that will give me an extra week to recover. He said he was sure he could get anyone to give a test. I do need to spend some time and come up with a decent exam for the ELI kiddos,

    I’ve also run this past the husband.

    Here’s the deal. Every time I work out, I have problems with heartburn. Almost every single night it wakes me up. It’s not as bad as it was with the expired Nexxium — that was the utter worse I’ve seen in ages. But I am still waking up. Most of the time I can roll over and go back to sleep but a lot of times I go ahead and get up, or have to get up and deal with it.

    I was having chest pains after lunch today. I’m 99% sure it was GERD. This is really sucking.

    Basically, the last time I was able to get rid of the GERD sympthoms, I was on Propulsid (sp), and had lost about 50 more pounds than I’ve lost so far. Well, the Propulsid isn’t available, and it’s going to be another year before I see 50 more pounds.

    Sigh.

    Well, at least I have my ducks in a row.

  • Restless Leg in Diabetics

    Here’s the weird thing, I was diagnosed with Restless Leg years before I was diagnosed with diabetes.

    Diabetes In Control – Restless Legs Syndrome Common in Diabetics

    Restless legs syndrome can be a major cause of sleep disruption in this population

    They also say it causes a lot of my “wake ups” but I don’t notice that near as much as I do the GERD wake ups.

  • Restless Leg in Diabetics

    Here’s the weird thing, I was diagnosed with Restless Leg years before I was diagnosed with diabetes.

    Diabetes In Control – Restless Legs Syndrome Common in Diabetics

    Restless legs syndrome can be a major cause of sleep disruption in this population

    They also say it causes a lot of my “wake ups” but I don’t notice that near as much as I do the GERD wake ups.

  • They keep trying…

    Here’s another attempt at a continuous glucose monitoring device.

    Diabetes In Control – Continuous, Non-Invasive Glucose Monitoring Device, Shows Positive Results in Cl

    Glucon announced last week the recent trial results of its flagship product, Aprise, a continuous, non-invasive, glucose monitoring device. The data was presented by Glucon V.P. of R&D Dr. Benny Pesach at the Diabetes Technology Society Standards Workshop on November 10, 2005 at the Fifth Annual Diabetes Technology Meeting in San Francisco.

  • They keep trying…

    Here’s another attempt at a continuous glucose monitoring device.

    Diabetes In Control – Continuous, Non-Invasive Glucose Monitoring Device, Shows Positive Results in Cl

    Glucon announced last week the recent trial results of its flagship product, Aprise, a continuous, non-invasive, glucose monitoring device. The data was presented by Glucon V.P. of R&D Dr. Benny Pesach at the Diabetes Technology Society Standards Workshop on November 10, 2005 at the Fifth Annual Diabetes Technology Meeting in San Francisco.

  • Symlin’s companion seems to be doing well

    Byetta will probably be a bigger money maker for Amylin since there is potential more patients for Byetta than Symlin (Symlin is for insuiln users, Byetta is being tested with oral medications).

    BYETTA Shown to Reduce Blood Sugar Levels When Added to Patients Treated With TZDs

    A1C, a measure of glucose control over the previous three months, improved by approximately 0.9 percentage points at the end of the 16-week study for subjects receiving twice daily 10 microgram subcutaneous injections of BYETTA in addition to their usual TZD or TZD plus metformin regimen, compared to those on their prior oral medications receiving placebo. At the beginning of the study, the average A1C of study participants was approximately 7.9 percent. Sixty-two percent of subjects receiving BYETTA who entered the study with an A1C greater than 7 percent achieved an A1C of 7 percent or less compared to sixteen percent of similar subjects on placebo. The American Diabetes Association recommends a target A1C of less than 7 percent.

  • Symlin’s companion seems to be doing well

    Byetta will probably be a bigger money maker for Amylin since there is potential more patients for Byetta than Symlin (Symlin is for insuiln users, Byetta is being tested with oral medications).

    BYETTA Shown to Reduce Blood Sugar Levels When Added to Patients Treated With TZDs

    A1C, a measure of glucose control over the previous three months, improved by approximately 0.9 percentage points at the end of the 16-week study for subjects receiving twice daily 10 microgram subcutaneous injections of BYETTA in addition to their usual TZD or TZD plus metformin regimen, compared to those on their prior oral medications receiving placebo. At the beginning of the study, the average A1C of study participants was approximately 7.9 percent. Sixty-two percent of subjects receiving BYETTA who entered the study with an A1C greater than 7 percent achieved an A1C of 7 percent or less compared to sixteen percent of similar subjects on placebo. The American Diabetes Association recommends a target A1C of less than 7 percent.

  • More making diabetes better

    I ordered another device and received it today. It is an eZwrap from Animas. It slides into your IR1250 (or 1200) pump and gives you a place to wrap up extra tubing.

    I just installed it and it works well. The shortest length works well if I use my upper adbomen but I have to use the next longest lenth for my lower belly. However that means I end up with too much tubing.

    Worth the cost.

  • More making diabetes better

    I ordered another device and received it today. It is an eZwrap from Animas. It slides into your IR1250 (or 1200) pump and gives you a place to wrap up extra tubing.

    I just installed it and it works well. The shortest length works well if I use my upper adbomen but I have to use the next longest lenth for my lower belly. However that means I end up with too much tubing.

    Worth the cost.